February 28, 2025

New Member: Welcome in our cluster to CAVIGEN UG

New Member: Welcome in our cluster to CAVIGEN UG
Go back

CAVIGEN develops thermoformed microstructures for cell culture, including microcavities, porous microcavities, sensor-integrated microcavities (sensor arrays), and microchannels. Its patented technology enables precise oxygen measurement in 3D cell cultures, enhancing the physiological relevance of in vitro models, improving drug development processes, and reducing the need for animal testing.

CAVIGEN’s business model follows a razor-and-blade approach, offering a measurement device alongside disposable sensor arrays for organoid generation and analysis. In addition, the company provides custom development services to integrate its microstructures into existing systems.

Target customers include pharmaceutical companies, CROs, biotech firms, and organ-on-chip manufacturers developing advanced in vitro models. Currently preparing for market entry, CAVIGEN is testing its first prototypes with academic research groups and industry partners while actively seeking strategic partners and investors to accelerate adoption within the pharmaceutical sector.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
A Vaccine for Parkinson’s?

A Vaccine for Parkinson’s?

The Parkinson Foundation has awarded three Innovation Prizes for 2026, including—for the first time—the Manfred Moggert-Kemper Prevention Prize. Prof. Dr. Chi Wang Ip and Assistant Professor Dr. Rhonda McFleder from the Department of Neurology at the University Hospital of Würzburg (UKW), as well as Prof. Dr. Mathias Munschauer from the University Hospital of Heidelberg (UKHD), […]

read more
Study from Heidelberg: Does Targeted Preparation Help with Recovery After Colon Cancer Surgery?

Study from Heidelberg: Does Targeted Preparation Help with Recovery After Colon Cancer Surgery?

Do patients recover more quickly after colorectal cancer surgery if they have previously completed a structured preparatory program? Researchers at Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital are investigating this question in the newly launched PREHAB-PEER study. The Federal Ministry of Research, Technology, and Space is funding the project with approximately 3.45 million […]

read more
Building Better Sandwich Immunoassays: A Toolbox for Biopharma Development Teams

Building Better Sandwich Immunoassays: A Toolbox for Biopharma Development Teams

Immunoassay development used to just mean getting a classic plate-based ELISA up and running. Today, that “standard” ELISA has exploded into many antibody pair-based formats, from homogeneous TR‑FRET assays to multiplexed MSD or Luminex panels—each with its own advantages and pitfalls. The data these assays generate is more robust than ever, but so is the […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp